Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer
Recruitment status was Not yet recruiting
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tissue and blood samples from patients with early-stage non-small cell lung cancer.
Genetic: DNA methylation analysis
Genetic: polymerase chain reaction
Other: laboratory biomarker analysis
|Official Title:||Epigenetic Changes as Prognostic Markers in Patients With Early Stage Non-Small Cell Lung Cancer|
- Aberrant DNA methylation patterns [ Designated as safety issue: No ]
- Definition of subgroups of patients at greater risk for recurrent or metastatic disease [ Designated as safety issue: No ]
- Prognostic indicators for disease-specific and overall survival [ Designated as safety issue: No ]
|Study Start Date:||July 2010|
|Estimated Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
- Evaluate aberrant methylation patterns in tissue and serum samples from patients with early-stage non-small cell lung cancer (NSCLC) to validate the Johns Hopkins single institutional study.
- Attempt to define subgroups of patients at greater risk for recurrent or metastatic disease who may benefit from more aggressive adjuvant therapeutic regimens.
- Develop prognostic indicators for disease-specific and overall survival.
- Define new potential molecular targets for therapy.
OUTLINE: Archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by methylation-specific PCR. Analyses are then compared with the preliminary data from the Johns Hopkins institutional study.
|Principal Investigator:||Malcolm V. Brock, MD||Sidney Kimmel Comprehensive Cancer Center|